Home › Research › Brain scans and imaging
Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis
Stage EC, Svaldi D, Phillips M, Canela VH, Duran T, Goukasian N, Risacher SL, Saykin AJ et al.. Alzheimer's research & therapy, 2020-08-05
Topic: Amyloid, tau and blood-test diagnosis
Background A substantial number of patients clinically diagnosed with Alzheimer's disease do not harbor amyloid pathology. We analyzed the presence and extent of tau deposition and neurodegeneration in amyloid-positive (AD) and amyloid-negative (nonAD) ADNI subjects while also taking into account age of onset (< or > 65 years) as we expected that the emerging patterns could vary by age and presence or absence of brain amyloidosis. Methods One hundred and ten early-onset AD (EOAD), 121 EOnonAD, 364 late-onset AD (LOAD), and 175 LOnonAD mild cognitive impairment (MCI) and dementia (DEM) subjects were compared to 291 ADNI amyloid-negative control subjects using voxel-wise regression in SPM12 with cluster-level family-wise error correction at p FWE < 0.05). A subset of these subjects also received 18 F-flortaucipir scans and allowed for analysis of global tau burden. Results As expected, relative to LOAD, EOAD subjects showed more extensive neurodegeneration and tau deposition in AD-relevant regions. EOnonAD MCI showed no significant neurodegeneration, while EOnonAD DEM showed bilateral medial and lateral temporal, and temporoparietal hypometabolism. LOnonAD MCI and LOnonAD DEM showed diffuse brain atrophy and a fronto-temporo-parietal hypometabolic pattern. LOnonAD and EOnonAD subjects failed to show significant tau binding. Conclusions LOnonAD subjects show a fronto-temporal neurodegenerative pattern in the absence of tau binding, which may represent underlying hippocampal sclerosis with TDP-43, also known as limbic-predominant age-related TDP-43 encephalopathy (LATE). The hypometabolic pattern observed in EOnonAD DEM seems similar to the one observed in EOAD MCI . Further investigation into the underlying etiology of EOnonAD is warranted.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Stage, E. C., Svaldi, D., Phillips, M., Canela, V. H., Duran, T., Goukasian, N., et al. (2020). Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis. Alzheimer's research & therapy. https://doi.org/10.1186/s13195-020-00647-w
Vancouver
Stage EC, Svaldi D, Phillips M, Canela VH, Duran T, Goukasian N, et al. Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis. Alzheimer's research & therapy. 2020. doi:10.1186/s13195-020-00647-w. PMID: 32758274.
BibTeX
@article{stage2020-32758274,
author = {Stage, E. C. and Svaldi, D. and Phillips, M. and Canela, V. H. and Duran, T. and Goukasian, N. and Risacher, S. L. and Saykin, A. J. and others},
title = {{Neurodegenerative changes in early- and late-onset cognitive impairment with and without brain amyloidosis}},
journal = {Alzheimer's research \& therapy},
year = {2020},
doi = {10.1186/s13195-020-00647-w},
pmid = {32758274},
url = {https://doi.org/10.1186/s13195-020-00647-w}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Methods One hundred and ten early-onset AD (EOAD), 121 EOnonAD, 364 late-onset AD (LOAD), and 175 LOnonAD mild cognitive impairment (MCI) and dementia (DEM) subjects were compared to 291 ADNI amyloid-negative control subjects using voxel-wise regression in SPM12 with cluster-level family-wise error correction at p FWE < 0.05).
- Results As expected, relative to LOAD, EOAD subjects showed more extensive neurodegeneration and tau deposition in AD-relevant regions.
- EOnonAD MCI showed no significant neurodegeneration, while EOnonAD DEM showed bilateral medial and lateral temporal, and temporoparietal hypometabolism.
- LOnonAD and EOnonAD subjects failed to show significant tau binding.
New to this subject? Start with our plain-English guide: Brain scans & tests →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 24 of the 58 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer's research & therapy) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32758274) |
| Free to read | 2 / 2 | Free to read |
| Points | 24 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 24 of the 58 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Brain scans and imaging
Also tagged “brain-amyloidosis”
2 studies in the library carry the topic tag “brain-amyloidosis”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.